Mankind Pharma Ltd. · NSE:MANKIND
Mankind Pharma — Q4 FY26 Earnings Presentation
33 slides from Mankind Pharma's earnings presentation, May 19, 2026
Slide 1: Cover letter to stock exchanges: Investor Presentation
~ Mankind/II,._ May 19, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Investor Presentation Pursuant to
Slide 2: Q4 & FY26
• Mankind//JJJ,,,. J~$gle, Q4 & FY26 May, 2026
Slide 3: Index
~ Mankind/I/JI,. J~.t',# Index 03 Additional Information • Mankind Pharma at a Glance (FY26) • Key Milestones • Expansion in Specialty and Super Specialty Segments 01 Financial Performance • Key Strengths • Key Financials – Q4 FY26 • Strategy Going Ahead • P & L Highlights – Q4 & FY26 • Financials -
Slide 4: Financial Performance
• Mankind//JJJ,,,. J~$gle, n
Slide 5: Q4 FY26 - Key Financial Snapshot
Q4 FY26 - Key Financial Snapshot Financials / Margins Growth Capital Efficiency • Mankind//JJJ,,,. J~~ge, 3,443 11.8% 12% / 41% Revenue (INR Cr) YoY Growth ROCE / Adj. ROCE 1 910 / 26.4% 32.7% 3,932 EBITDA (INR Cr)/ Margin YoY Growth Net Debt (INR Cr) 933 / 27.1% 31.1% 1.1x Adj. EBITDA 2 / Margin Yo
Slide 6: P&L Highlights - Q4 & FY26
YoY QoQ YoY • Mankind//JJJ,,,. J~~ge, INR Cr Q4FY26 Q4FY25 Q3FY26 FY26 FY25 Growth Growth Growth Revenue from Operations 3,443 3,079 11.8% 3,567 -3.5% 14,278 12,207 17.0% (A=B+C) Domestic Business (B) 2,886 2,544 13.4% 3,046 -5.3% 12,217 10,675 14.4% i. Domestic Business (ex CH) 2,673 2,366 12.9% 2,
Slide 7: Key Financial Metrics
Key Financial Metrics1 Cash Flow from Operations (INR Cr) CAPEX (INR Cr) ROCE2 • Mankind//JJJ,,,. J~~ge, CFO to ~------. ~------. ~------. CAPEX as I ~------. ~------. I 84% I I 80% I I 89% I 3.8% I 4.3% I 5.2% I EBITDA % of Rev ~-----..! ~-----..! ~-----..! ~-----..! ~-----..! With BSV With BSV 389
Slide 8: Business Updates
Cig Mankindil> Jeroing Life Business Updates
Slide 9: Strong Growth in Domestic Revenue
Strong Growth in Domestic Revenue1,2 • Mankind//JJJ,,,. J~~ge, INR Cr 14% 13% _____. 12% ____-. 10,675 12,217 9,447 8,453 13% _. - - 2,544 2,886 FY23 FY24 FY25 FY26 Q4FY25 Q4FY26 Domestic revenue increased 13% YoY driven by double digit growth in Mankind business, supported by strong growth in BSV
Slide 10: BSV: Increased chronic share in FY26
1- Increased chronic share by 190 bps1 in FY26 ,----------------------, • Mankind//JJJ,,,. ~~~ SEWV~ Ufe, + BSV bringing life to life = : 1 I ~ Mankind!!/► Se,v""a'Li[e, BSV ~"""''"'"'"' : 1 I Consistent focus to increase chronic contribution BSV’s super specialty portfolio Mankind Consolidated 40.4
Slide 11: Q4 FY26 - Therapy wise Performance
~- i) Q4 FY26 - Therapy wise Performance • Mankind//JJJ,,,. J~~ge, High Ranks across Acute and Chronic Areas Q4FY26 - Sales Mix representing Diversified Therapy Presence Rank in FY 21-26 CAGR MS% Key Therapy Areas CVM 11% (Q4FY26) 16% (Q4FY26) Mankind2 IPM 2% • Cardiovascular • Anti-Infectives Chron
Slide 12: FY26 Business Update
FY26 Business Update1 • Mankind//JJJ,,,. J~~ge, 2,3 Mankind volume increased by 180 bps vs 130 bps IPM in FY26 1.1x outperformance to IPM chronic in FY26 8.0% 7.5% 9.9% 8.2% 39% 37% 40% 39% 13.3 11.9 12.3 2.8% 2.3% 1.6% 9.8 2.8% 4.4% 4.2% 4.3% 4.2% 2.7% 2.3% 1.4% 0.5% IPM Mankind IPM Mankind FY25 FY
Slide 13: Consistently Built and Scaled Brands
Consistently Built and Scaled Brands • Mankind//JJJ,,,. J~~ge, CAGR Key Brands1 >INR 500 Cr Brand Families FY 21 FY 26 (FY21-26) > INR 500 Crore 0 3 14.4% ... '' l-Camitine l-Tartrate, Mecobala;;;- &Folic Acid Tablets " mMIIARIAN &HYDROCHLOROTHW!Df IABlflS IP -· NUROKIND'·LC > INR 200 Crore 7 13 12.
Slide 14: Consistently Expanding Our Portfolio Towards Specialty
1- Consistently Expanding Our Portfolio Towards Specialty Reference Market Prod~;///► Brand Launched Market 5 Year Therapy Area Indication Size (INR Cr) – Rationale (Year) CAGR FY26 • Neptaz – In-licensed from Novartis. Strong Revenue and Volume growth. N e ptaz # (FY22) ~ Heart Failure 8911 17% Ran
Slide 15: Consumer Healthcare
Consumer Healthcare Consumer Healthcare Segment Revenue (INR Cr) • Mankind//JJJ,,,. J~~ge, EBITDA % 19.9% 19.0% 18.7%1 20.1% 21.4%1 go/o __ 2%__,... ~ ~ 879 809 692 706 20% - 178 213 FY23 FY24 FY25 FY26 Q4FY25 Q4FY26 Revenue growth of 20% YoY in Q4FY26 primarily driven by strong growth in Manforce
Slide 16: Strong Corporate Identity Complements Brand Recall
1- Strong Corporate Identity Complements Brand Recall.. . • Mankind//JJJ,,,. J~~ge, Strategically selected national and regional brand ambassadors Corporate Brand Ambassadors Dominant Brands Consumer Healthcare Brand Ambassadors #1 Condom Brand Market Share – 28% Sunny Leone [I] Manasvi Mamgai #1 An
Slide 17: Consumer Healthcare marketing campaigns
xx Launching the Valentine’s Day King Dot & King Thin Valentine’s Day Digital Video Campaign for Epic Aura Digital Video Video Campaign for Women’s Day Campaign #SheCanCarryBoth Highlighting Massager Promotion EPIC THINX across Postpartum Depression platforms On-ground brand activations in UP, Punja
Slide 18: Revenue from Exports
Revenue from Exports (INR Cr)1 2,061 1,532 813 535 557 296 FY23 FY24 FY25 FY26 Q4FY25 Q4FY26 Revenue from International business witnessed muted growth of 4% YoY in Q4FY26 impacted due to geo-political headwinds Mankind (excluding BSV) has launched 4 new products in FY26 taking the total launche
Slide 19: ESG Key Highlights
Key Key Key Adoption of Highlights Initiatives Priorities Technologies Zero Reportable Lost Time accidents across all manufacturing units • 10% increase in total Renewable energy • Voluntary ESG report FY25 • Double Materiality Assessment and • Digitalization of Contractor safety usage in FY26 than
Slide 20: ESG Goals & Status FY26
ESG Goals & Status FY26 Area GOAL1 Status FY26 No Lost Time Accident across Occupational Health and Safety ZERO Lost Time Accidents all manufacturing & New Project sites Carbon Neutral (Scope 1 & 72%2 reduction in FY26 Scope 2 emissions) 100% by FY’30 from base year FY21 disposal for co-processing H
Slide 21: Additional Information
ig Mankindil> Vy) Additional Information
Slide 22: Mankind Pharma at a Glance (FY26)
Rank in Prescriptions over Rank by volume in Rank by value in IPM1 / Consumer Healthcare brands Market the last nine years1 IPM1 Gynaecology ranked #1 in their categories1 Leadership Brand families1 worth FY26 Revenue FY26 Domestic Revenue Mar’26 Field force2 INR 50/100 Cr+ Scale Revenue CAGR FY21-2
Slide 23: Key Milestones
1995 2004 2007-10 2018-19 2020-21 2022 2023 2024 2025 Entered into in-licensing Acquired 1. Acquired Rivotril agreements with: 100% stake in Successfully listed BSV Limited in CNS from Roche Commenced Entered chronic Entered Acquired brands 1. Astra Zeneca - Paonta Sahib on NSE and BSE 2. Udaipur an
Slide 24: Expansion in Specialty and Super Specialty Segments
Mass Market Specialty Chronic (Acute/ Chronic / Semi Chronic) (Cardio / Diabeto / CNS) Consumer Healthcare (OTC) BSV - Super Specialty Targeted Medical Practitioners Targeted Medical Practitioners Targeted Medical Practitioners GP CP MD MD DM KOL GT MT ECOM MD DM KOL INR 11,338 Cr 28%/ 39% ~INR 879
Slide 25: Key Strengths
India revenues contribute 86% of total revenues in FY26 Focus on Focus on Consistent CFO/ EBITDA ratio of ~80% domestic domestic during FY26 business Volume- Best in class business cash growth driven #2 rank by volume in IPM1 conversion by metrics 1 affordability 9 2 Strong 75% of manufacturing in-h
Slide 26: Strategy Going Ahead
Consolidate market share in increased CVM - Deeper penetration in incremental CVM1 (62% in FY21 to 72% in FY26) driven by volume focused growth and scaling up brands. Increasing chronic share - Increasing presence in chronic therapies (Diabetes – Empagliflozin, and Insulin Glargine, Respiratory – In
Slide 27: Financials - Steady Growth Trajectory
Revenue (INR Cr) Strong Growth in Domestic Revenue (INR Cr) 18% 15% CAGR CAGR 14,278 12,207 12,217 10,260 10,675 8,749 9,447 7,782 8,453 7,595 6,214 5,564 FY21 FY22 FY23 FY24 FY25 FY26 FY21 FY22 FY23 FY24 FY25 FY26 Revenue from Exports (INR Cr) EBITDA (INR Cr) and Margin %(2) 26.7% 25.8% 21.9% 24.7%
Slide 28: Key Performance Highlights
• Mankind//JJJ,,,. J~~ge, Key Performance Highlights FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 Value Growth YoY in IPM (%) 11.3 12.6 12.5 11.1 17.7 10.6 8.5 7.5 8.2 Market share by Value in IPM (%) 3.9 4.0 4.1 4.3 4.3 4.4 4.4 4.8 4.7 Market Ranking by Value in IPM (x) 4 4 4 4 4 4 4 4 4 CVM share
Slide 29: Shareholding Pattern
BSE Ticker 543904 1.4% 4.4% 10.4% NSE Symbol MANKIND # of Shares outstanding* 41,28,28,328 11.3% Share Price* 2,005.80 Market Cap. (INR Cr)* 82,805 % Free Float 27.5% 72.5% Free Float Market Cap. (INR Cr) 22,771 Industry Pharmaceuticals Promoters FPI & Bodies Corporate Mutual Funds Retail Others Sha
Slide 30: Annexures: Formulas and definitions
• ROCE = (EBIT for the year ) / (Capital employed less cash) o EBIT excludes other income o Capital employed is the sum of total equity, total borrowings, total lease liabilities and deferred tax liabilities (net) less deferred tax assets and Cash. • Adjusted ROCE = (Adjusted EBIT for the year )/ (A
Slide 31: Q4 & FY26 Earnings Call Details
Date 20th May, 2026 Time 12:00 PM – 01:00 PM IST Link Zoom Call https://us06web.zoom.us/webinar/register/WN_gjCF6TrYR9eK24zP-RYSZQ 30
Slide 32: Disclaimer
• Mankind//JJJ,,,. J~~ge, The statements, are as on date and may contain forward-looking statements like the words “believe”, “expects”, “anticipate”, “aim”, “will likely result”, “would”, “will continue”, “contemplate” “intends”, “plans”, “estimates”, “seek to”, “future”, “objective”, “projects”, “
Slide 33: Thank You
Thank You For more information please visit our website: https://www.mankindpharma.com For specific queries, contact: Abhishek Agarwal Head - Investor Relations & Strategy 011 – 46846700 Ext. 3532 Investor.relations@mankindpharma.com